|
A
|
|
|
Aweeka, Francesca T., Pharm.D.
- Current Title(s):
- Director, Drug Research Unit
- Professor in Residence
- First Year on UCSF Faculty: 1988
- Education:
- Bachelor of Science, University of Southern California, 1981
- Pharm.D., University of California, San Francisco, 1985
- Resident in Clinical Pharmacy, University of California, San Francisco, 1985-86
- Pharmacokinetics/Pharmacodynamics Research Fellow, 1986-88
- Licensure:
- Licentiate in Pharmacy, 1985
- Specialty:
- Pharmacokinetics and pharmacodynamics: primarily in anti-viral and antimalarial drugs
University of California, San Francisco, School of Pharmacy
C-152, Box 0622, 521 Parnassus Avenue, San Francisco, CA 94143-0622
Phone: (415)-476-0339, Fax: (415)576-0307, Email: faweeka@sfghsom.ucsf.edu
|
|
|
Professional Biography
Dr. Aweeka's research interests are in the areas of pharmacokinetics and pharmacodynamics: primarily for anti-viral and antimalarial drugs. She has carried out various projects evaluating the disposition of antiviral drugs near the site of pharmacological activity (i.e. active drug within peripheral blood mononuclear cells). In addition, her expertise lies in investigating the disposition of drugs in distinct populations including pregnant women and patients with concomitant illnesses such as renal disease. More recently her work has expanded to the study of the pharmacology of artemisinin based antimalarial therapy in children in Uganda and in the context of antiviral drugs required for patients co-infected with malaria and HIV. Malaria and HIV co-infection is a growing problem in sub-Saharan Africa. Dr. Aweeka directs the Drug Research Unit (DRU) at San Francisco General Hospital which is based within the Department of Clinical Pharmacy and is Prinicipal Investigator of the UCSF Pharmacology Laboratory for the AIDS Clinical Trials Group (ACTG), the International, Maternal and Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) and the Pharmacology Core of the UCSF Center for AIDS Research. The DRU specializes in state of the art analytical methodologies for antiretroviral drugs within plasma and target tissues. In addition, the DRU had developed assays for the most commonly prescribed antimalarial drugs.
|
|
Selected Peer-reviewed Publications
- Aweeka FT, Kang M, Yu JY, Lizak P, Alston B, Chung RT; AIDS Clinical Trials Group 5092s Study Team.Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med. 2007 Jul;8(5):288-94.
- Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH; NIAID AIDS Clinical Trials Group.The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS. 2006 Sep 11;20(14):1833-41.
- German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007 Mar 15;44(6):889-91.
|
|
A
|
